A2 Katsausartikkeli tieteellisessä aikauslehdessä

Biomarkers for Immunotherapy of Oral Squamous Cell Carcinoma: Current Status and Challenges




Julkaisun tekijät: Almangush Alhadi, Leivo Ilmo, Mäkitie Antti A.

Kustantaja: FRONTIERS MEDIA SA

Julkaisuvuosi: 2021

Journal: Frontiers in Oncology

Tietokannassa oleva lehden nimi: FRONTIERS IN ONCOLOGY

Lehden akronyymi: FRONT ONCOL

Volyymi: 11

Sivujen määrä: 5

ISSN: 2234-943X

eISSN: 2234-943X

DOI: http://dx.doi.org/10.3389/fonc.2021.616629

Verkko-osoite: https://www.frontiersin.org/articles/10.3389/fonc.2021.616629/full


Tiivistelmä
Oral squamous cell carcinoma (OSCC) forms a major health problem in many countries. For several decades the management of OSCC consisted of surgery with or without radiotherapy or chemoradiotherapy. Aiming to increase survival rate, recent research has underlined the significance of harnessing the immune response in treatment of many cancers. The promising finding of checkpoint inhibitors as a weapon for targeting metastatic melanoma was a key event in the development of immunotherapy. Furthermore, clinical trials have recently proven inhibitor of PD-1 for treatment of recurrent/metastatic head and neck cancer. However, some challenges (including patient selection) are presented in the era of immunotherapy. In this mini-review we discuss the emergence of immunotherapy for OSCC and the recently introduced biomarkers of this therapeutic strategy. Immune biomarkers and their prognostic perspectives for selecting patients who may benefit from immunotherapy are addressed. In addition, possible use of such biomarkers to assess the response to this new treatment modality of OSCC will also be discussed.

Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Last updated on 2021-24-06 at 09:44